

# **GMP-COMPLIANT PROPAGATION OF HUMAN MULTIPOTENT MESENCHYMAL STROMAL CELLS**

EVA ROHDE, KATHARINA SCHALLMOSER, CHRISTINA BARTMANN,  
ANDREAS REINISCH, AND DIRK STRUNK

*Medical University of Graz, Graz, Austria*

## **Contents**

- 1 Introduction
- 2 Acronyms and Definitions
  - 2.1 Mesenchymal Stromal Cells
  - 2.2 Somatic Stem Cell Therapy
  - 2.3 Good Manufacturing Practice
  - 2.4 Cell-Based Medicinal Products
  - 2.5 Human Platelet Lysate
- 3 Approaches
  - 3.1 Adherence to Principles of GMP in a Preclinical Developmental Process
  - 3.2 Efficient Standardized MSC Propagation Using Low Cell Seeding Density
  - 3.3 Superior MSC Proliferation Resulting from HPL-Driven as Compared to FBS-Driven Cultures
  - 3.4 Contamination Risks Can Be Minimized in Rational MSC Propagation Procedures
- 4 Testing Methods
  - 4.1 Safety and Efficacy of CBMP in Preclinical Stage
  - 4.2 Quality Controls During Cell Culture (In-Process Controls) and Final Product Release Criteria
  - 4.3 MSC Functionality and Potency Assays
- 5 Conclusion
- References